US Stock Movement: Kodiak Sciences Plummets on October 2nd Due to Sharp Correction, Financing Pressure, and Regulatory Uncertainty

Interpretation of Kodiak Sciences’ Sharp Decline on October 2

Keywords: Surge Correction, Financing Pressure, Approval Uncertainty

1. On September 28, 2026, after the company announced the DAYBREAK Phase III trial met its endpoints, the stock price soared 177.96% in a single day, triggering a rapid short-term valuation re-adjustment and correction pressure at the highs on October 2.

2. As of September 30, 2026, the company remains in the pre-commercialization stage, with quarterly cash burn exceeding 60 million USD and current cash of about 126 million USD. There is a potential need for equity financing in the future, and the risk of dilution has attracted attention.

3. On September 28, 2026, DAYBREAK announced the key trial results, but Zenkuda still needs to submit a Biologics License Application and obtain regulatory approval. The commercialization, pricing, and competitive landscape remain undetermined.

(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only and does not constitute investment advice.)